Skip to main content

Table 1 Results of histomorphometrical analysis of effects of the treatments on LuCaP 23.1 and bone

From: Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment

  BV/TV (%) TUV/TV (%) TB.TH. (μM) TB. N. (MM-1) TB.SP. (μM) OS.S./BS (%) OS.TH. (μM) OB.PM./BPM. (%) N.OC./BS (%)
Control 23.09 ± 9.34 30.62 ± 5.75 94.89 ± 31.75 6.06 ± 1.41 76.87 ± 20.90 7.24 ± 1.82 4.57 ± 0.29 15.97 ± 5.08 1.91 ± 0.35
ZOL 36.51 ± 7.86 17.68 ± 6.79a 145.7 ± 31.64 5.08 ± 0.53 52.29 ± 13.51 3.96 ± 1.87 5.27 ± 0.45 8.46 ± 1.42a 0.83 ± 0.46a
DOC 29.46 ± 8.56 28.29 ± 11.18 81.53 ± 20.45 5.61 ± 0.90 100.6 ± 24.88 6.73 ± 1.84 5.21 ± 0.36 14.17 ± 4.36 1.19 ± 0.61
ZOL + DOC 40.38 ± 8.73a 11.13 ± 3.41a,b 118.5 ± 25.56 5.59 ± 0.51 61.48 ± 21.83 4.77 ± 1.01 4.98 ± 0.40 11.92 ± 5.90 0.77 ± 0.42a
  1. Tumored tibiae were harvested after seven weeks of treatment and embedded in methacrylate. Analysis was performed on Goldner-stained longitudinal sections of tibiae (n = 5 per group).
  2. Results are presented as a mean ± SD.
  3. a p < 0.5 vs. control group
  4. b p = 0.11 group 2 vs. group 4